|
Hemogenyx Pharmaceuticals PLC on Monday said it has received clearance to begin pediatric enrolment in its phase 1 trial of a leukemia treatment. The London-headquartered biopharmaceutical company focused on treatments for blood diseases said the institutional review board at MD Anderson Cancer Centre approved an amendment to the clinical protocol of the company’s ongoing trial for HG-CT-1. The approved amendment expands the eligibility criteria for the trial to include children and adolescents, which broadens the patient pool and builds on the safety and early efficacy signals already observed in adult participants. HG-CT-1 is Hemogenyx’s CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia. ‘Securing IRB clearance to proceed with pediatric enrolment in our HG-CT-1 clinical trial is a major milestone. It marks the transition of HG-CT-1 into the pediatric setting, where treatment options remain limited, and demonstrates the continued momentum of our development program,’ said Hemogenyx Chief Executive Officer Vladislav Sandler. ‘This expansion not only increases the potential reach and impact of HG-CT-1 but also underscores the value of the company’s strong intellectual property portfolio, which underpins our pipeline and supports long-term growth.’ The company will provide further updates as both adult and pediatric patient enrolment progresses. Shares in Hemogenyx Pharmaceuticals were up 7.7% at 1,162.89 pence in London on Monday afternoon. The stock has more than doubled from 526.40p over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
